109 A new study has revealed a significant global rise in anal cancer incidence and mortality, particularly in Central and Eastern Europe, the UK, and Denmark. The research, conducted by a team of international scientists, underscores the urgent need for enhanced awareness, vaccination, and early detection measures to combat the growing public health challenge. The findings were published in the European Journal of Cancer Prevention. Anal cancer, once considered a rare malignancy, is now showing a worrying upward trend in many parts of the world. According to the study, which analysed data from 1994 to 2020, the highest age-standardised mortality rates were observed in Slovakia, the UK, and Denmark. For instance, in Slovakia, mortality rates reached 0.9 per 100,000 men and 0.40 per 100,000 women by 2020. Similarly, the UK reported rates of 0.24 per 100,000 men and 0.35 per 100,000 women, highlighting the severity of the issue in Europe. The research also noted that while some countries, such as the Philippines and Mexico, still maintain relatively low mortality rates, the general trend across most nations is concerning. The highest incidence rates between 2008 and 2012 were in Germany, at 1.65 per 100,000 men and 2.16 per 100,000 women, which coincided with the rise in mortality rates. One of the primary factors driving the increase in anal cancer cases is the human papillomavirus (HPV). The study highlighted that HPV-related squamous cell carcinoma (SCC) is the most common form of anal cancer, particularly in regions with high incidence rates. The correlation between HPV and anal cancer is particularly pronounced in countries with higher HPV prevalence, such as those in Eastern Europe, where the virus is found in approximately 21% of women – nearly double the global average of 11%. HPV is also a major factor in the development of other cancers, such as cervical and vulvar cancers, and its transmission between the anus and cervix is well-documented. The introduction of HPV vaccination programmes in the mid-2000s was a critical step in reducing the spread of the virus and, by extension, the incidence of HPV-related cancers. But the study notes that it is still too early to observe significant reductions in anal cancer rates among adults, as the vaccination campaigns primarily target younger populations. The upward trend in anal cancer incidence and mortality is not limited to Europe. The study reports that countries like the United States, Canada, and Brazil have also seen significant increases in both metrics. For instance, in the US, the annual percent change in mortality rates was 3.3% for women and 1.2% for men, highlighting the growing public health challenge this formerly uncommon cancer poses. The researchers point to several factors contributing to these increases, including changes in sexual behaviours, higher rates of HIV infection, and the ageing population. Anal cancer is strongly associated with sexual practices, particularly those that involve multiple partners and unprotected intercourse, which facilitate the spread of HPV. The study also emphasises the effect of HIV on anal cancer rates because the virus’s immunosuppression increases the risk of getting HPV-related cancers. Given the alarming trends, the study’s authors call for enhanced efforts to prevent and detect anal cancer. Vaccination against HPV remains one of the most effective measures to reduce the risk of anal cancer. Countries with high vaccination coverage, such as those in Northern Europe and Australia, are expected to see long-term benefits, although these effects may take years to become apparent in cancer incidence and mortality statistics. In addition to vaccination, the researchers emphasise the importance of early detection and treatment. Anal cancer is often diagnosed at an advanced stage, particularly in older populations, which contributes to higher mortality rates. Improved screening methods, such as digital anal rectal examinations and high-resolution anoscopy, could play a crucial role in catching the disease earlier, when it is more treatable.